Sponsor name | Trials on EUCTR | Trials due to report results | % Reported | Trials with inconsistent data | Major? |
---|---|---|---|---|---|
Novartis | 1547 | 990 | 99.9% | 339 | major |
GlaxoSmithKline | 1198 | 727 | 100.0% | 377 | major |
Pfizer | 914 | 581 | 99.3% | 234 | major |
Merck Sharp & Dohme (MSD) | 870 | 514 | 100.0% | 216 | major |
Roche | 806 | 420 | 99.0% | 204 | major |
Sanofi S.A. | 768 | 400 | 100.0% | 298 | major |
Astrazeneca | 749 | 421 | 97.9% | 147 | major |
Johnson & Johnson | 593 | 340 | 99.4% | 154 | major |
Eli Lilly | 492 | 322 | 99.1% | 85 | major |
Medical University of Vienna | 460 | 289 | 93.1% | 36 | major |
Amsterdam UMC | 416 | 75 | 37.3% | 55 | major |
Bristol-Myers Squibb | 412 | 222 | 100.0% | 108 | major |
Boehringer Ingelheim | 400 | 314 | 100.0% | 53 | major |
Hospitals of Paris (AP-HP) | 369 | 66 | 25.8% | 57 | major |
Bayer | 346 | 256 | 100.0% | 56 | major |
Amgen Inc | 308 | 202 | 100.0% | 66 | major |
Novo Nordisk | 284 | 187 | 100.0% | 51 | major |
KU Leuven | 275 | 201 | 96.0% | 10 | major |
Radboud University Medical Centre | 274 | 97 | 84.5% | 61 | major |
Abbvie | 271 | 139 | 99.3% | 69 | major |
Gilead Sciences Inc | 269 | 172 | 100.0% | 71 | major |
Rigshospitalet | 267 | 158 | 52.5% | 26 | major |
Takeda | 262 | 155 | 100.0% | 68 | major |
No Sponsor Name Given | 252 | 84 | 67.9% | 26 | major |
Erasmus University | 240 | 17 | 76.5% | 34 | major |
UCB | 239 | 123 | 100.0% | 94 | major |
Aarhus University | 224 | 139 | 66.9% | 16 | major |
Charité-Universitätsmedizin Berlin | 214 | 168 | 100.0% | 7 | major |
Agostino Gemelli University Polyclinic | 196 | 19 | 10.5% | 114 | major |
University of Groningen | 191 | 18 | 66.7% | 13 | major |
Leiden University | 183 | 19 | 36.8% | 17 | major |
Merck KGaA | 179 | 124 | 100.0% | 37 | major |
Utrecht University | 171 | 30 | 53.3% | 47 | major |
IRCCS Ospedale San Raffaele | 165 | 56 | 98.2% | 15 | major |
University College London | 163 | 90 | 98.9% | 9 | major |
Astellas | 159 | 110 | 100.0% | 33 | major |
Ghent University | 157 | 74 | 81.1% | 42 | major |
Servier Laboratories | 154 | 117 | 100.0% | 22 | major |
Celgene | 150 | 73 | 100.0% | 42 | major |
Allergan | 147 | 106 | 99.1% | 31 | major |
University of Oxford | 146 | 86 | 100.0% | 0 | major |
Imperial College London | 145 | 103 | 100.0% | 3 | major |
Karolinska University Hospital | 141 | 32 | 34.4% | 14 | major |
Medical University of Graz | 140 | 98 | 87.8% | 9 | major |
Biogen | 140 | 92 | 95.7% | 31 | major |
IRCCS Azienda Ospedaliero-Universitaria di Bologna | 135 | 6 | 83.3% | 34 | major |
Novartis Vaccines | 132 | 65 | 100.0% | 63 | major |
Eisai Inc. | 131 | 69 | 100.0% | 46 | major |
Helsinki University | 130 | 37 | 32.4% | 12 | major |
Pierre Fabre S.A. | 122 | 99 | 99.0% | 8 | major |
Oslo University Hospital | 122 | 27 | 40.7% | 12 | major |
Odense University Hospital | 120 | 77 | 90.9% | 16 | major |
University of Birmingham | 118 | 53 | 100.0% | 7 | major |
Chiesi Farmaceutici S.p.A | 117 | 78 | 100.0% | 24 | major |
Vertex Pharmaceuticals, Inc. | 117 | 60 | 100.0% | 42 | major |
Shire | 115 | 79 | 100.0% | 23 | major |
Hospices Civils de Lyon | 114 | 27 | 22.2% | 12 | major |
European Organisation for the Research and Treatment of Cancer (EORTC) | 111 | 66 | 98.5% | 22 | major |
Abbott | 109 | 87 | 96.6% | 18 | major |
King’s College London | 108 | 73 | 98.6% | 6 | major |
Université libre de Bruxelles | 106 | 28 | 67.9% | 12 | major |
National Cancer Institute Italy (Istituto Nazionale dei Tumori) | 106 | 4 | 50.0% | 23 | major |
Herlev and Gentofte Hospital | 105 | 65 | 70.8% | 13 | major |
Ipsen | 104 | 64 | 100.0% | 22 | major |
Teva | 100 | 78 | 98.7% | 17 | major |
Actelion Pharmaceuticals Ltd | 99 | 65 | 100.0% | 26 | major |
H. Lundbeck A/S | 95 | 73 | 98.6% | 14 | major |
Regeneron Pharmaceuticals Inc. | 94 | 37 | 100.0% | 31 | major |
Unicancer | 92 | 17 | 88.2% | 4 | major |
CSL Behring | 89 | 52 | 100.0% | 30 | major |
Karolinska Institutet | 89 | 45 | 82.2% | 9 | major |
Incyte Corporation | 88 | 26 | 92.3% | 25 | major |
Daiichi Sankyo | 86 | 48 | 100.0% | 21 | major |
University of Munich (Ludwig-Maximilians) | 85 | 51 | 72.5% | 6 | major |
Alexion Pharmaceuticals, Inc | 85 | 38 | 97.4% | 31 | major |
Maastricht University | 85 | 25 | 36.0% | 27 | major |
Otsuka | 84 | 56 | 100.0% | 18 | major |
Fundació Clínic per a la Recerca Biomèdica | 84 | 8 | 25.0% | 30 | major |
Innsbruck Medical University | 82 | 54 | 92.6% | 6 | major |
University of Cologne | 82 | 54 | 98.1% | 2 | major |
Guy's and St Thomas' NHS Foundation Trust | 82 | 50 | 96.0% | 3 | major |
Antoni van Leeuwenhoek Hospital | 82 | 8 | 50.0% | 7 | major |
Genentech | 80 | 61 | 100.0% | 10 | major |
CHU de Toulouse | 78 | 18 | 16.7% | 18 | major |
Vrije Universiteit Brussel | 78 | 12 | 41.7% | 8 | major |
Alcon | 76 | 44 | 100.0% | 31 | major |
University of Dundee | 74 | 69 | 100.0% | 1 | major |
Menarini Group | 72 | 58 | 100.0% | 7 | major |
University of Leeds | 72 | 52 | 98.1% | 0 | major |
University Hospital Tübingen | 72 | 48 | 85.4% | 4 | major |
Technical University of Munich | 72 | 46 | 100.0% | 14 | major |
European Institute of Oncology | 72 | 3 | 0.0% | 18 | major |
Bispebjerg Hospital | 71 | 51 | 54.9% | 7 | major |
NHS Greater Glasgow and Clyde | 71 | 40 | 100.0% | 2 | major |
Vall d'Hebron University Hospital | 71 | 23 | 82.6% | 16 | major |
LEO Pharma A/S | 70 | 56 | 100.0% | 11 | major |
The Newcastle upon Tyne Hospitals NHS Foundation Trust | 69 | 56 | 94.6% | 1 | major |
Galderma R&D | 69 | 55 | 98.2% | 8 | major |
Heidelberg University Hospital | 68 | 41 | 90.2% | 3 | major |
Cliniques Universitaires Saint-Luc | 67 | 20 | 90.0% | 28 | major |
CHU Clermont-Ferrand | 67 | 15 | 0.0% | 7 | major |
Hospital de la Santa Creu i Sant Pau | 67 | 12 | 66.7% | 13 | major |
ACCORD (University of Edinburgh & NHS Lothian) | 66 | 44 | 97.7% | 2 | major |
Queen Mary University of London | 65 | 42 | 100.0% | 5 | major |
Baxter | 64 | 49 | 95.9% | 8 | major |
University Erlangen-Nuremberg | 64 | 37 | 81.1% | 5 | major |
Gothenburg University | 64 | 18 | 33.3% | 11 | major |
University of Nottingham | 63 | 57 | 100.0% | 1 | major |
Manchester University NHS Foundation Trust | 63 | 53 | 100.0% | 1 | major |
Mario Negri Institute | 63 | 31 | 100.0% | 15 | major |
University of Turku | 63 | 18 | 50.0% | 3 | major |
CHU de Bordeaux | 63 | 12 | 16.7% | 12 | major |
Almirall S.A. | 62 | 51 | 100.0% | 7 | major |
Ferring Pharmaceuticals | 60 | 54 | 100.0% | 3 | major |
The Royal Marsden NHS Foundation Trust | 60 | 29 | 82.8% | 2 | major |
Fondazione Giovanni Pascale | 60 | 1 | 0.0% | 12 | major |
Sapienza University of Rome | 59 | 2 | 100.0% | 7 | major |
Hannover Medical School | 58 | 49 | 93.9% | 3 | major |
Hvidovre Hospital | 58 | 37 | 48.6% | 8 | major |
AOU Policlinico di Modena | 58 | 10 | 10.0% | 24 | major |
HOVON Foundation | 58 | 5 | 100.0% | 7 | major |
Policlinico San Matteo | 58 | 5 | 0.0% | 38 | major |
University Hospitals of Leicester NHS Trust | 56 | 45 | 97.8% | 5 | major |
University of Hamburg | 56 | 30 | 93.3% | 1 | major |
Belfast Health and Social Care Trust | 55 | 46 | 97.8% | 0 | major |
Mundipharma | 55 | 45 | 93.3% | 5 | major |
Skåne University Hospital | 55 | 15 | 40.0% | 11 | major |
Octapharma AG | 54 | 34 | 100.0% | 14 | major |
King's College Hospital NHS Foundation Trust | 53 | 41 | 97.6% | 2 | major |
Johannes Gutenberg University of Mainz | 53 | 36 | 72.2% | 5 | major |
BioMarin Pharmaceutical Inc | 53 | 23 | 95.7% | 9 | major |
University of Antwerp | 53 | 7 | 42.9% | 8 | major |
University of Freiburg | 52 | 30 | 80.0% | 3 | major |
Goethe University | 52 | 23 | 69.6% | 4 | major |
CHU de Nantes | 52 | 13 | 69.2% | 5 | major |
Barts Health NHS Trust | 51 | 44 | 100.0% | 4 | major |
University Hospital Southampton NHS Foundation Trust | 51 | 20 | 70.0% | 2 | major |
Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) | 51 | 3 | 0.0% | 23 | major |
Cambridge University Hospitals NHS Foundation Trust | 50 | 42 | 95.2% | 0 | major |
Dresden University of Technology | 50 | 29 | 100.0% | 5 | major |